Clinical Trial Update: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3, randomized, double-blind trial evaluating oral linaclotide for irritable bowel syndrome with constipation (IBS-C)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• Linaclotide (linaclotide)

Snippet

Sponsor: AstraZeneca | Conditions: Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Status: COMPLETED | Results posted: 2016-09-27